Clinical Trials Logo

Gastric Bypass Surgery clinical trials

View clinical trials related to Gastric Bypass Surgery.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03402347 Completed - Clinical trials for Gastric Bypass Surgery

Ex Vivo Evaluation of Laser Induced Thermal Tissue Damage

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This clinical study has been initiated to assess the effect of laser exposure on human skin and determine the threshold for tissue damage. The tissue specific effects will be evaluated through histological evaluation. Excess skin from corrective surgery (gastric bypass or similar) will be donated for this study. Skin samples will be subjected to titrating laser treatment with varying laser intensity and exposure time.

NCT ID: NCT01938469 Completed - Obesity Clinical Trials

Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery

Start date: September 2010
Phase: N/A
Study type: Interventional

Analyze the effect of meal pattern (meal number, frequency, and form) on satiety, gut peptides, insulin, and glucose levels in individuals before and 12-15 months after gastric bypass surgery (GBP).

NCT ID: NCT01568437 Completed - Obesity Clinical Trials

Transversus Abdominis Plane (TAP) Block in Laparoscopic Gastric-bypass Surgery

Start date: January 2012
Phase: Phase 3
Study type: Interventional

Laparoscopic gastric-bypass surgery (LGBS) is one of the surgical treatments for morbid obesity, which is performed under general anesthesia. TAP block is an analgesic strategy covering the dermatomes from T6 to L1 and consists of injecting local anesthetic in the TAP between the costal margin and the iliac crest, where the thoracolumbar nerves (T6-L1) are located. As far as the investigators know, this analgesic technique has never been studied in LGBS. The investigators objective is to determine whether an ultrasound (US)-guided TAP block provides improved analgesia during the first 24 hours after laparoscopic gastric-bypass surgery, compared to conventional therapy only.

NCT ID: NCT00571220 Completed - Obesity Clinical Trials

Mechanisms of Diabetes Control After Weight Loss Surgery

Start date: September 2005
Phase: N/A
Study type: Observational

Obesity and type 2 diabetes (T2DM) are increasing in the US. One third of patients seeking bariatric surgery have T2DM. Although all surgeries result in significant weight loss and often 'cure' the T2DM, the rapid onset and the magnitude of the benefits of gastric bypass (GBP) on T2DM has thus far baffled clinical scientists. Limited data suggest that the improvement in T2DM after GBP occurs very rapidly, and may not be wholly accounted for by weight loss. Secretion of incretins (gut peptides secreted in response to meals which enhance insulin secretion) is impaired in T2DM and improves after GBP, possibly due to the specific anatomical changes after this surgery. While some determinants of impaired insulin secretion, such as glucotoxicity, improve equally after diet or surgical weight loss, the improvement in the incretin effect after GBP might be specific to this surgery. The aim of this study is to determine whether the magnitude of the incretin effect on insulin secretion is greater after GBP than after an equivalent diet-induced weight loss. We will compare, in obese patients with diabetes, randomized to very low calorie diet or to GBP, the effect of an equivalent weight loss on the incretin effect (difference in insulin secretion after comparable oral and intravenous (IV) glucose loads). As more obese diabetic patients undergo GBP, understanding the mechanisms that produce improvement in their diabetes is increasingly important.